Merck builds new TICE BCG manufacturing facility to triple capacity

Merck is building a new manufacturing facility for TICE BCG, investing more than $650 million. The facility aims to triple manufacturing capacity, but opening has been delayed beyond the original end-of-2026 target due to mechanical interdependencies.

“This investment reaffirms Merck’s longstanding commitment to producing this medicine, and all our medicines, for patients who need them.”merck.com

• 1 source
• merck.comAddressing the global shortage of TICE BCG - Merck.comMerck, Co., Inc., Rahway, NJ, USAMay 30, 2025

Summarized from public sources; check the original articles before acting on it.